Results 41 to 50 of about 9,527 (221)

Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). [PDF]

, 2017
In November 2016, the American College of Physicians (ACP) published a clinical practice guideline on the management of acute and recurrent gout. This guideline differs substantially from the latest guidelines generated by the American College of ...
A Chhana, A Qaseem, A Qaseem, AB Gutman, Alexander K. So, CF Kuo, CY Lam Erwin, D Khanna, D Khanna, DF Ransohoff, DH Solomon, DJ McCarty, DJ McCarty, DL Sackett, E Jutkowitz, E Pascual, F Lioté, F Perez-Ruiz, F Perez-Ruiz, F Perez-Ruiz, F Rees, F Sivera, Frédéric Lioté, H Park, HK Choi, HR Schumacher, HR Schumacher, HR Schumacher Jr., HS Baraf, Hyon K. Choi, J Li-Yu, JA Singh, JA Singh, JE Seegmiller, JN Loeb, JS Faires, JS Sundy, Kenneth G. Saag, KG Saag, Lisa K. Stamp, LK Stamp, M Doherty, MA Becker, MA Becker, MA Becker, MA Becker, Michael Doherty, N Bellamy, N Dalbeth, N Dalbeth, N Dalbeth, N Dalbeth, Nicola Dalbeth, O Aati, P Richette, P Richette, Pascal Richette, PC Robinson, PG Shekelle, PP Khanna, PS Hench, R Halpern, R Jackson, RM McLean, Robert Terkeltaub, SI Hung, SY Lim, T Bardin, T Neogi, Thomas Bardin, TM Ko, U Kiltz, V Strand   +72 more
core   +1 more source

Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK. [PDF]

, 2013
Excess reactive oxygen species (ROS) formation can trigger various pathological conditions such as inflammation, in which xanthine oxidase (XO) is one major enzymatic source of ROS.
Busso, N., Ives, A., Nomura, J., So, A., Tamura, M., Tsujimoto, S., Yamanaka, Y.   +6 more
core   +3 more sources

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST):a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia [PDF]

, 2014
Introduction: Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase
Annemans, Burns, Committee, Evans, Feig, Hansson, Ioachimescu, Khanna, Kuo, Luk, Pal, Schumacher, Smith, Strasak, Strasak, Wortmann, Zhang   +16 more
core   +6 more sources

Enantioconvergent Access to Chiral S(VI) Stereocenters by Kinetic Resolution of Sulfonimidoyl Chlorides

Angewandte Chemie, Volume 138, Issue 2, 9 January 2026.
An enantioconvergent approach for the kinetic resolution of S(VI) stereocenters that leverages the electrophilic reactivity of the chiral sulfur atom is described. The catalytic process provides access to sulfonimidoyl chlorides and sulfonimidates, which are among the least studied S(VI) functionalities.
Arko Das, Shree Krishna Dhakal, Ramon Trevino, Seth O. Fremin, Vy T. B. Nguyen, Arka Porey, Sachchida Nand, Chandan Kumar Giri, Daniel J. Wherritt, Hadi D. Arman, Oleg V. Larionov   +10 more
wiley   +2 more sources

Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations [PDF]

, 2019
Background Recruitment to clinical trials can be challenging. Methods that improve the efficiency of trial recruitment are needed to increase successful study completions.
Flynn, Robert, MacDonald, Thomas, Mackenzie, Isla, Rogers, Amy   +3 more
core   +4 more sources

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, EarlyView.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]

, 2019
ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott, Goldfarb, David S, Jalal, Diana, Pillinger, Michael, Saag, Kenneth G, Schechter, Bruce M, Terkeltaub, Robert, Valiyil, Ritu, White, William B   +8 more
core   +1 more source

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout

Arthritis Care &Research, EarlyView.
Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Pascal Richette, Anouk Walter‐Petrich, Quang Dinh Nguyen, Matthieu Resche‐Rigon, Quang Huy Dinh Nguyen, Minh Duc Do, Thao Phuong Mai, Tuan Duc Nguyen, Fernando Perez‐Ruiz, Emmanuel Letavernier, Tristan Pascart, Augustin Latourte, Hang Korng Ea, Thomas Bardin   +13 more
wiley   +1 more source

Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers.

PLoS ONE, 2016
UnlabelledThe present study aimed to investigate the pharmacokinetic properties of febuxostat in healthy Chinese male volunteers and evaluate whether the two formulations of febuxostat 40-mg and 80-mg tablets are bioequivalent.
Zhu Luo, Feng Nan, Jia Miao, Zhihui Chen, Mei Li, Maozhi Liang   +5 more
doaj   +1 more source